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most from expedited symptomatic
diagnosis? Construction of a ranking order
by a modified Delphi technique
Willie Hamilton1*, Sally Stapley1, Christine Campbell2, Georgios Lyratzopoulos3, Greg Rubin4 and Richard D. Neal5
Abstract
Background: This study aimed to answer the question ‘for which cancers, in a symptomatic patient, does
expediting the diagnosis provide an improvement in mortality and/or morbidity?’
Methods: An initial ranking was constructed from previous work identifying ‘avoidable deaths’ for 21 common
cancers in the UK. In a two-round modified Delphi exercise, 22 experts, all experienced across multiple cancers,
used an evidence pack summarising recent relevant publications and their own experience to adjust this ranking.
Participants also answered on a Likert scale whether they anticipated mortality or morbidity benefits for each
cancer from expedited diagnosis.
Results: Substantial changes in ranking occurred in the Delphi exercise. Finally, expedited diagnosis was judged to
provide the greatest mortality benefit in breast cancer, uterine cancer and melanoma, and least in brain and
pancreatic cancers. Three cancers, prostate, brain and pancreas, attracted a median answer of ‘disagree’ to whether
they expected mortality benefits from expedited diagnosis of symptomatic cancer.
Conclusions: Our results can guide future research, with emphasis given to studying interventions to improve
symptomatic diagnosis of those cancers ranked highly. In contrast, research efforts for cancers with the lowest
rankings could be re-directed towards alternative avenues more likely to yield benefit, such as screening or
treatment.
Keywords: Cancer, Diagnosis, Primary health care, Modified Delphi technique
Background
It is widely believed that the sooner a cancer is diag-
nosed, the better the outcomes for that patient will be
[1]. There is strong evidence from screening trials in
some cancers that this is true for the asymptomatic pa-
tient. However, once the patient has developed symp-
toms, the evidence for mortality benefit from expediting
the diagnosis is much weaker, and relies on observa-
tional data [2–4]. Even so, it is still considered axiomatic
that avoiding delay in symptomatic cancer diagnosis is
beneficial, in reducing mortality and morbidity, provid-
ing symptom relief and possible improvements in
psychological well-being. This view underpins the many
interventions in recent years aimed at improving survival
rates from cancer, especially in those countries with a
relatively poor cancer performance, such as the United
Kingdom (UK) and Denmark [5].
Patients certainly value early diagnosis of cancer [6].
However, not all cancers behave in the same way and
there are many different types. Survival differs greatly
across the common cancers; so does ease of diagnosis –
shown by the number of primary care consultations pre-
diagnosis [7], times to diagnosis [8], and the proportion
having an emergency presentation [9]. In some poor-
prognosis cancers, there is an element of nihilism with
cure considered unlikely whatever the time to diagnosis
(though relief of symptoms and prolongation of life
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remain important) [10]. Such nihilism may pervade the
research agenda; for instance, lung cancer has consist-
ently attracted much lower research funding than the
other three common cancer sites [11].
If expediting symptomatic diagnosis is of greater (or
lesser) value across different cancer sites, then it would
help the research community to know which cancer sites
have most (or least) to gain. Those with most to gain
might preferentially receive research funding targeted on
early cancer diagnosis. In contrast, research effort in
cancers with less to gain would focus more on preven-
tion, development of effective screening, or treatment.
This study aimed to answer the question ‘for which
cancers, in a symptomatic patient, does expediting the
diagnosis provide an improvement in mortality and/or
morbidity?’ In the absence of trial evidence, alternative
methods had to be employed. Thus, we used a Delphi
exercise, combining the available evidence with the
pooled responses of experts – an approach which has
not been tried before to answer this question.
Methods
Mortality benefits
Phase 1 – Construction of the initial ranking
Phase 1 had two stages. The first used data from a study
of international differences in cancer survival published
by Abdel-Rahman et al. [12] This paper reported for
each of the 22 commonest cancers the percentage of
additional (deemed ‘avoidable’) UK deaths within 5 years
of diagnosis in patients aged 15–99, derived from the
highest survival estimates for 13 other European coun-
tries, in 1995–1999. There is a widely held view that
these international differences represented to a consider-
able extent diagnostic delays [1], though treatment dif-
ferences, differences in organisation of health care and
registration processes will have contributed. By exten-
sion, the ranking order from this paper would broadly
reflect those cancers where there is the most or least to
gain from expedited diagnosis. This created Column A1
in Table 1.
The second stage adjusted Column A1 to accommo-
date cancers with high survival, in the belief that the
Abdel-Rahman paper would fail to capture fully any sur-
vival benefit from expedited diagnosis in this group. For
example, testicular cancer has very high survival, and
international survival differences are small. However, this
could be because the disease is extremely chemo-
sensitive (which it is) or because it is a cancer which is
diagnosed quickly, or occurs in younger patients – or
more than one of these. Therefore, high survival may
mask any advantages from rapid diagnosis. For each can-
cer, UK 5-year survival was identified from the Office for
National Statistics publication for England, relating to
2005–9 [13]. For each cancer site, the percentage
surviving 5 years was added to the figures in Column
A1, giving a half weighting to the survival figures (shown
in column Shalf ). This process led to the removal of oral
cavity cancers from Column A2, as survival statistics
separated oral cancers into subgroups; we could identify
no composite figure.
Phase 2: the Delphi survey – round 1
We followed best practice in consensus methods for this
[14]. We invited 189 participants to a modified Delphi
exercise by e-mail, with a reminder to non-responders
after three weeks: 22 replied and all participated in both
rounds of the Delphi, lasting from March to May, 2014.
They were chosen for their general expertise in the can-
cer field and included general practitioners, public health
professionals, academic researchers (targeting individuals
in these groups with specific professional responsibilities
for cancer) and clinicians linked to cancer networks. We
specifically excluded cancer specialists with single site
expertise on methodological grounds [15]. The initial in-
vitation list was generated by the steering group; if an in-
vitee recommended a colleague suitably qualified to
respond we extended the invitation. The invitation in-
cluded an explanatory letter, a resource pack and an
Excel table for replies. The letter and resource pack de-
scribed the research question,
Table 1 Derivation of the figures for Delphi Round 1
Cancer Site Column A1 Column Shalf Column A2
Breast 26.8 11.2 38.0
Uterus 25 10.2 35.2
Kidney 27.7 7.1 34.8
Prostate 24 10.7 34.7
Melanoma 22 11.5 33.5
Hodgkin disease 20.3 10.9 31.2
Cervix 17 8.8 25.8
Larynx 16.6 8.8 25.4
Colon 12.3 7.2 19.5
Ovary 13.5 5.6 19.1
Non-Hodgkin lymphoma 10.1 8.4 18.5
Rectum 10.2 7.4 17.6
Multiple myeloma 11.7 4.9 16.6
Bladder 8 7.1 15.1
Testis 1.4 12.8 14.2
Leukaemia 8.1 5.8 13.9
Stomach 11.6 2.2 13.8
Brain 9 2.0 11.0
Lung 7.2 1.2 8.4
Oesophagus 4.5 1.7 6.2
Pancreas 2.5 0.5 3.0
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‘For this particular cancer, in a patient who has
symptoms from the cancer, does expediting the
diagnosis provide an improvement in mortality?’
The resource pack was derived from a systematic re-
view first carried out in 2010 [16], and updated in De-
cember 2013/January 2014, though published after this
study completed [17]. The aim of the review was to de-
termine the impact of different patient, primary care and
secondary care intervals (and combinations of these) on
stage at diagnosis and/or survival. 121 papers were in-
cluded. Each was assigned a category based on the study
design (see Additional file 1) though most were observa-
tional studies of individual patients (category 3). A sam-
ple from the resource pack is shown in Additional file 2
(full pack available from authors).
Delphi participants were allocated a ‘purse’ of 40
points to be used to adjust the position of cancers in
Column A2 [18]. Positive or negative points could be
used - both counting equally to the total spend. All 40
points had to be used, with +/−10 being the maximum
for a single cancer site. Delphi participants were asked
to use their personal experience, plus the evidence in the
resource pack, to make these adjustments. We did not
request details of how much participants used the re-
source pack, and how much they relied on personal ex-
perience (though most round 1 replies from participants
included comments upon the lengthy time involved in
making their judgements, suggesting the resource pack
was used considerably).
Weighting of phase 2, round 1 of the Delphi exercise
We weighted the responses to ensure that Round 1 of
the Delphi exercise achieved an overall influence of 33 %
for the whole study. Column A2 – the initial ranking
sent to Delphi participants – totalled 436 points, with a
standard deviation of 10.5. The weighting within Phase 2
aimed to give 2/3rd of 436 points to Round 1, i.e. 291
points, to achieve the overall influence of 33 %. The
process for calculating the weighting entailed: a) calcula-
tion of the mean change in points allocated by Delphi
participants to each cancer site (this could be a positive
or negative number); b) negative mean changes were
temporarily made positive in order to avoid any ‘cancel-
ling out’ effect, and the total of the 21 mean values was
calculated to give the overall magnitude of change; c)
291 was divided by this total magnitude of change, to give
a conversion factor (8.61); d) originally negative mean
changes were restored to negative (reversing stage b); e)
individual mean changes for each cancer were multiplied
by the conversion factor, and then added to the original
points in Column A2 to give Column B.
To estimate how much influence the Delphi participants
actually had, the adjusted changes can be expressed as
multiples of the standard deviation of the values in
Column A2. The greatest adjusted change would have
been if every participant had given one particular site the
maximum allowed 10 points. Once multiplied by the con-
version factor of 8.61, the greatest adjusted change would
be 86 points, or 8.2 standard deviations. Thus any cancer
could have been promoted from the bottom of the ranking
to the top, or vice versa.
Likert rating of mortality and morbidity statements
Delphi participants also rated statements relating to
mortality and morbidity benefits for each cancer site.
These were: ‘Expedited cancer diagnosis brings mortality
benefits in this cancer site’ and ‘Expedited cancer
diagnosis brings morbidity benefits such as improved
treatment options and psychological benefit in this can-
cer site.’ Treatment options were described further to
include pain or other symptom relief. Responses were
requested on a 5-point Likert scale: Strongly disagree;
Disagree; Undecided; Agree; Strongly Agree. For ana-
lysis, we did not assume the responses were equally
spaced; instead we report the median response (modal
responses differed in only 7 of the 42 answers, always to
an adjacent response).
Phase 2: the Delphi survey – round 2
All 22 responders to Round 1 of Phase 2 were invited to
participate in Round 2. The pre hoc principle was that
Round 2 should have a total influence on the whole
process of 17 %. Each participant was allocated a ‘purse’
of seven points which could be used positively or
negatively to one or more cancer sites. Unlike Round 1,
participants were not obliged to ‘spend’ all – or any – of
their points if they were happy with Column B. Column
C was constructed from Column B, plus the mean
change in allocated points in Round 2.
To test whether the survival adjustment in the second
stage of Phase 1 was reversed in the Delphi process, we
calculated the correlation between the change from
Columns A1 to A2, and the change from A2 to Column
C (the entire Delphi process). Analyses used Stata,
version 13 [19].
No ethical committee review was required for this
study, as is the norm with Delphi studies and with re-
search involving staff; participants were deemed to have
consented by returning the questionnaire.
Results
Figure 1 shows the results of Phase 1 of the project,
which created Column A2, plus the changes made in the
Delphi process, Columns B and C. In total, 160 UK and
29 international experts were invited to participate in
the Delphi process. Of these 189, the email was undeliv-
erable in 12 participants, nine declined, (five being too
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busy and four considering their expertise insufficient);
there were 146 non-responders. Twenty-two com-
pleted returns (21 from the UK and one from
Denmark) were received: ten academic researchers in
cancer diagnosis, six GPs, four clinicians with cancer
network responsibilities and two public health profes-
sionals with a specific cancer remit in their posts: all
22 also participated in Round 2. Seven allocated no
points in the second round, stating Column B was
correct. The correlation coefficient between change
from Column A1 to Column A2 (Phase 1) and the
change from Column A2 to Column C (i.e. Phase 2,
the Delphi process) was +0.43 (p = 0.05), suggesting
that the survival adjustment in Column A2 was help-
ful. The final relative positions of the 21 cancer sites
after the Delphi process are shown in Figure 2. The
Likert responses are shown in Table 2.
Discussion
Summary of the main findings
This is the first study to try to rank cancers by potential
mortality benefit from expedited symptomatic diagnosis.
The final ranking, although not definitive, suggests that
cancers with the greatest potential benefit are breast, uterus
and melanoma; in contrast, pancreas and brain were con-
sidered to have the least potential benefit. The Likert re-
sponses for whether mortality gains were to be expected
from expediting symptomatic diagnosis were concordant
with the final rankings. Perceived morbidity benefits were
largely unrelated to the mortality ranking for cancer sites.
Fig. 1 the initial ranking (Column A2), plus results of the two Delphi rounds (Columns B and C)
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Strengths and limitations
This study had two distinct phases: construction of the
initial ranking and the Delphi process. Both have
methodological limitations. The initial Column A1 was
predicated upon the view that European cancer survival
differences reflected differences in timeliness of diagno-
sis in part at least. We used the best information avail-
able, and considered it preferable to provide an initial
ranking rather than offering Delphi participants a start-
ing point of all cancers being equal – while accepting
the possibility of an ‘anchoring’ effect [20]. This effect
occurs when people are given a specific value for a
quantity, before measuring (or in our case, adjusting) the
quantity itself. The Abdel-Rahman paper uses data
which is now close to twenty years old; although im-
provements in diagnosis and treatment may have changed
the ranking somewhat, the purpose of the initial ranking
was to provide a reasonable starting point based – in part
at least – on diagnostic differences. More recent data –
had it been available – would have reflected the improve-
ments in UK cancer diagnostic pathways in recent years,
making international variation less helpful in showing up
any effect from improved diagnostics.
The adjustment for survival was also debatable; the ra-
tionale was that patients with cancers with high cure
rates could still benefit from expedited diagnosis. One
internal finding suggests that this process was valuable:
the positive correlation between the change in scores in-
troduced by the survival adjustment and the change in
scores from the Delphi exercise. In short, the Delphi ex-
ercise moved in the same direction as the survival ad-
justment, rather than reversing it. Furthermore, there
was ample latitude in the Delphi exercise to change any
misplaced cancer. A cancer ranked last could have be-
come first, and vice versa, though no cancer changed
ranking as dramatically as this. Other choices in Phase 1,
including different weightings, would have generated dif-
ferent starting points for the Delphi participants; they
might not have led to important differences in the final
outputs. One unfortunate effect of the survival adjust-
ment was that oral cancer was lost to the Delphi
process, as we could not find appropriate survival fig-
ures. The initial position of oral cancer was mid-ranking,
between rectal cancer and non-Hodgkin lymphoma. We
cannot know what its final position would have been
had it entered the Delphi exercise.
The Delphi exercise had two rounds. A feature of the
Delphi process is reiteration, with structured feedback
and subsequent rounds helping to develop consensus.
The number of rounds is a balance between maintaining
recruitment and allowing change. We saw little alter-
ation in Round 2 – with nearly a third of the panel sug-
gesting no change at all was needed – and hence the
value of a third round would probably have been limited.
Our number of Delphi participants was within the usual
range [21]; of 189 invited, 22 took part, all of whom
completed both rounds. We do not know why most of
the non-responders declined. The evidence pack was large,
and many participants indicated that the exercise required
both considerable time and intellectual engagement. We
cannot know if a different panel would have yielded differ-
ent results. Deliberately, we excluded patients and surgical
Figure 2 Relative positions for 21 cancer sites in terms of potential
benefit to be had from expedited symptomatic cancer diagnosis
Table 2 Median Likert responses of statements that expedited symptomatic cancer diagnosis brings mortality or morbidity benefits
Expedited symptomatic cancer diagnosis brings mortality benefits Expedited symptomatic cancer diagnosis brings morbidity
benefits
Strongly agree
Agree Bladder, breast, cervix, colon, larynx, lung, melanoma, ovary,
rectum, testis, uterus
Bladder, brain, colon, kidney, larynx, leukaemia, lung, myeloma,
oesophagus, ovary, stomach
Undecided Hodgkin’s disease, kidney, leukaemia, myeloma, non-Hodgkin’s
lymphoma, oesophagus, ovary, stomach
Breast, cervix, Hodgkin’s disease, melanoma, non-Hodgkin’s
lymphoma, pancreas, prostate, rectum, testis, uterus
Disagree Brain, pancreas, prostate
Strongly disagree
Note: the median response for ovary and mortality was between ‘agree’ and ‘undecided’ – thus we have placed it in both cells.
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specialists from the Delphi process: both groups largely
have expertise in a single cancer site (or grouped sites, such
as urological cancers). We believed that the Delphi partici-
pants should be able to comment across a wide range of
cancers to allow them to adjust the rankings appropriately.
A future exercise could extend to a much wider commu-
nity, including patients, the public and specialists.
The findings from this study would change if major
improvements in treatment for a particular cancer were
available. For example, were a new drug for pancreatic
cancer to be developed, then expedited symptomatic
diagnosis of pancreatic cancer would presumably in-
crease in importance. Therefore, our rankings are of
value only for the present time. They also only pertain
to the 21 cancers we included. Omission of other can-
cers from the ranking does not mean no benefit is to be
expected, just that any such benefit is unreported.
Interpretation
This is the first exercise of this nature that we know of.
Thus we cannot directly compare it with other published
studies. The research question offered to Delphi partici-
pants made no reference to division of the pre-
diagnostic period into patient intervals (before entry into
healthcare) and healthcare provider/system intervals
[22]. Thus the results may pertain to both, and hence
have possible relevance to either awareness campaigns
or the design of diagnostic services.
The findings on the potential morbidity benefit were
unexpected. Although no cancer sites attracted a median
response of ‘disagree’ or ‘strongly disagree,’ ten had a
median response of ‘undecided’. This was despite the
emphasis given to the possibility of palliation and symp-
tom relief. Three of these cancer sites – breast, melan-
oma and prostate – have a sizeable literature relating to
over-diagnosis, though this mostly relates to screen-
detected cancer. It is plausible that, for these sites, Del-
phi participants believed that the morbidity benefits
were outweighed by harms, though it is hard to see how
this could extend to the other seven cancers.
Three cancers – breast, uterus and melanoma – were
ranked as being most likely to result in improved mor-
tality outcomes through expedited symptomatic diagno-
sis, and there was a moderate gap between these cancer
sites and the next group. In the UK, diagnostic services
for breast cancer are highly streamlined, such that in the
English National Health Service women with almost any
breast complaint (other than pain) are assessed rapidly
for the possibility of cancer. This facility – which is the
most comprehensive of all the various cancer diagnostic
services – is consonant with our findings. We cannot
know if the presence of such a scheme influenced Delphi
participants, who could reasonably have inferred from
the existence of such a service that it was particularly
warranted. The generally accepted benefits of breast
cancer screening may have encouraged Delphi partici-
pants to consider breast to be particularly worthy of
expedited diagnosis [23], even though the screening
population is asymptomatic, and were not included in
this study.
Uterine cancer has a similarity to breast cancer, in that
a single presentation, post-menopausal bleeding, domi-
nates [24]. Services for investigation of post-menopausal
bleeding are also well-structured, and timely investigation
is the norm. In contrast to breast cancer or melanoma,
uterine cancer has not been considered for awareness
campaigns encouraging women with post-menopausal
bleeding to consult their doctors. Our results suggest this
should be considered.
Melanoma also has a characteristic symptom, a pig-
mented lesion. Times to diagnosis are generally short,
emergency admissions are rare, and few patients report
seeing their doctor three or more times before diagnosis
[7–9]. Some concerns about ‘over-diagnosis’ have been
raised for melanoma [25], based on a stable number of
deaths in the face of rising numbers of new diagnoses.
An alternative interpretation is that good services for
diagnosis of melanoma have led to improved survival,
despite an increased incidence.
Sixteen cancers are ranked in the middle of the rank-
ing, though for only one of them, prostate, did the
Delphi respondents give a median Likert answer of ‘dis-
agree’ to the statement that expedited symptomatic can-
cer diagnosis brought mortality benefits. Five cancers
within this large grouping had large changes in the Del-
phi exercise: bladder and lung were promoted, and
ovary, prostate and non-Hodgkin’s lymphoma fell. The
promotion of bladder may represent the clear survival
advantage of early bladder cancer diagnosis when com-
pared with advanced disease. The promotion of lung
cancer refutes some of the nihilism attaching to this sub-
ject; in the UK at the time of the Delphi exercise there
was considerable public publicity of lung cancer symp-
toms, as part of the Be Clear On Cancer campaign. Fur-
thermore, lung cancer resection rates are rising, and
newer treatments, tailored to specific cancer genotypes,
have entered mainstream practice. This circumstantial
evidence may have encouraged Delphi participants to
believe that expedited symptomatic diagnosis has bene-
fits – for some lung cancer patients. Ovary is similar to
bladder cancer in its sharp survival difference between
early and advanced disease, though, in this cancer,
advanced disease is the norm. Diagnostic testing has be-
come much easier, with the widespread use of Ca125
[26]. It is hard to explain why non-Hodgkin’s lymphoma
fell. Long-term results from a trial of surgery in prostate
cancer have yielded small benefits, though with additional
morbidity [27]. This is not the same as demonstrating
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benefits from expedited diagnosis. Furthermore, prostate
screening trials have disappointed, reporting no, or very
small benefits. This leaves a confusing picture, of small
benefits at best – commensurate with its final place in the
ranking.
Two cancers were deemed to be associated with the
smallest gains from expedited diagnosis throughout the
whole exercise: brain and pancreas. Both have very poor
prognoses, and this may have been uppermost in Delphi
participants’ minds [28]. Although expediting symptom-
atic diagnosis in these cancers may have less effect in
improving survival compared with other cancers, it does
not mean there is no value in trying to do so. The pri-
mary message is that we have to be realistic about what
it is possible to achieve. A clear implication can be
drawn: that research efforts should concentrate on other
aspects, such as prevention, development of novel
screening tools, including new biomarkers, and new tar-
geted therapeutic agents. Quite rightly, these cancers
with poor outcomes should receive preferential attention
and funding, but that this should focus on areas most
likely to offer tangible benefits.
Conclusion
This study has produced an initial ranking for the mortal-
ity benefit available from expedited symptomatic diagnosis
of cancer. It can guide future research directions, to en-
sure they have the maximum chance of making an impact.
It should not be used as an excuse to downgrade research
on cancer sites near the bottom of the ranking – but as a
pointer towards the optimum research direction.
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